Percent populations of myosin active states by thick filament zone
| Untreated (Fig. 3 d) . | |||
|---|---|---|---|
| % (±SEM) | P-zone | C-zone | D-zone |
| Activea | 11.1 (±0.8) | 7.4 (±0.5) | 8.8 (±0.8) |
| DRX | 54 (±2.5) | 40.1 (±1) | 47.7 (±1.9) |
| SRX | 35 (±5.5) | 52.5 (±4) | 43.6 (±5.4) |
| Mava (Fig. 4 c ) | |||
| Activea | 12.8 (±1.3) | 6.7 (±0.4) | 6 (±0.2)b |
| DRX | 53.9 (±3.7) | 33.4 (±1.1)b | 30.6 (±0.6)b |
| SRX | 33.3 (±10.8) | 59.9 (±3.6) | 63.4 (±2.7)b |
| PKA (Fig. 4 d ) | |||
| Activea | 10.3 (±0.7) | 5.7 (±0.3)b | 8.1 (±0.4) |
| DRX | 67.1 (±1.6)b | 60 (±1.4)b | 47 (±0.9) |
| SRX | 22.6 (±6.6) | 34.3 (±3.3)b | 44.9 (±2.7) |
| Change from untreated to mava (Fig. 4 a ) | |||
| Activea | 1.7 (±1.6) | −0.7 (±0.6) | −2.8 (±0.8) |
| DRX | −0.1 (±4.5) | −6.7 (±1.5) | −17.1 (±2) |
| SRX | −1.6 (±12.2) | 7.4 (±5.4) | 19.8 (±6.1) |
| Change from untreated to PKA (Fig. 4 b ) | |||
| Activea | −0.8 (±1.1) | −1.7 (±0.6) | −0.7 (±0.8) |
| DRX | 13.1 (±3) | 19.9 (±1.7) | −0.7 (±2.1) |
| SRX | −12.4 (±8.6) | −18.1 (±5.2) | 1.4 (±6) |
| SRX:DRX ratio (Fig. 4 e ) | |||
| Untreated | 0.6 (±0.1) | 1.3 (±0.1) | 0.9 (±0.1) |
| +Mava | 0.6 (±0.2) | 1.8 (±0.1)b | 2.1 (±0.1)b |
| +PKA | 0.3 (±0.1) | 0.6 (±0.1)b | 1.0 (±0.1) |
| Untreated (Fig. 3 d) . | |||
|---|---|---|---|
| % (±SEM) | P-zone | C-zone | D-zone |
| Activea | 11.1 (±0.8) | 7.4 (±0.5) | 8.8 (±0.8) |
| DRX | 54 (±2.5) | 40.1 (±1) | 47.7 (±1.9) |
| SRX | 35 (±5.5) | 52.5 (±4) | 43.6 (±5.4) |
| Mava (Fig. 4 c ) | |||
| Activea | 12.8 (±1.3) | 6.7 (±0.4) | 6 (±0.2)b |
| DRX | 53.9 (±3.7) | 33.4 (±1.1)b | 30.6 (±0.6)b |
| SRX | 33.3 (±10.8) | 59.9 (±3.6) | 63.4 (±2.7)b |
| PKA (Fig. 4 d ) | |||
| Activea | 10.3 (±0.7) | 5.7 (±0.3)b | 8.1 (±0.4) |
| DRX | 67.1 (±1.6)b | 60 (±1.4)b | 47 (±0.9) |
| SRX | 22.6 (±6.6) | 34.3 (±3.3)b | 44.9 (±2.7) |
| Change from untreated to mava (Fig. 4 a ) | |||
| Activea | 1.7 (±1.6) | −0.7 (±0.6) | −2.8 (±0.8) |
| DRX | −0.1 (±4.5) | −6.7 (±1.5) | −17.1 (±2) |
| SRX | −1.6 (±12.2) | 7.4 (±5.4) | 19.8 (±6.1) |
| Change from untreated to PKA (Fig. 4 b ) | |||
| Activea | −0.8 (±1.1) | −1.7 (±0.6) | −0.7 (±0.8) |
| DRX | 13.1 (±3) | 19.9 (±1.7) | −0.7 (±2.1) |
| SRX | −12.4 (±8.6) | −18.1 (±5.2) | 1.4 (±6) |
| SRX:DRX ratio (Fig. 4 e ) | |||
| Untreated | 0.6 (±0.1) | 1.3 (±0.1) | 0.9 (±0.1) |
| +Mava | 0.6 (±0.2) | 1.8 (±0.1)b | 2.1 (±0.1)b |
| +PKA | 0.3 (±0.1) | 0.6 (±0.1)b | 1.0 (±0.1) |